SBI Securities Co. Ltd. Invests $281,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

SBI Securities Co. Ltd. purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 7,130 shares of the company's stock, valued at approximately $281,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRSP. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $39,000. Western Pacific Wealth Management LP raised its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after buying an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $40,000. Darwin Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $43,000. Finally, Spire Wealth Management grew its stake in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Price Performance

CRSP traded up $2.22 on Friday, reaching $45.53. 1,884,937 shares of the company traded hands, compared to its average volume of 2,267,393. The stock's 50 day moving average price is $42.79 and its 200-day moving average price is $45.77. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $81.73. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -10.42 and a beta of 1.77.

Remove Ads

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CRSP shares. Stifel Nicolaus lowered their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a research note on Wednesday, February 12th. The Goldman Sachs Group lowered their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of "Hold" and an average target price of $73.11.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director John Greene bought 7,000 shares of CRISPR Therapeutics stock in a transaction on Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now directly owns 7,000 shares of the company's stock, valued at $313,950. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.